EU HE - ONCOVALUE Implementing value-based oncology care at European cancer hospitals: An AI-based framework for assessing real-life effectiveness of novel cancer therapies in real-time

 ONCOVALUE logo

Programme

HORIZON EUROPE

Call for proposal

HORIZON-HLTH-2022-TOOL-11

Funding scheme

HORIZON-RIA

Budget

€6,953,003.50

Start date

1st december 2022

Duration

48 months

Real-world data (RWD) on patient health status are collected from various sources, such as electronic health records and wearables. Harnessing the power of RWD is challenging but offers the possibility to unlock actionable healthcare insights.

The key objective of the EU-funded ONCOVALUE project is to collect and analyse RWD from European cancer hospitals and institutes as a means of assessing the effectiveness of novel cancer therapies. The consortium will use AI technologies to transform unstructured data from medical notes and images into real-world evidence made available to clinicians for treatment decision-making, and to regulatory bodies for developing guidelines. Collectively, ONCOVALUE will contribute to safer and more efficient therapies and technologies.

Link: https://cordis.europa.eu/project/id/101095245

Link: Home - Oncovalue

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.
Istituto di Ricovero e Cura a Carattere Scientifico
Sede legale: Via Piero Maroncelli, 40 - 47014 Meldola (FC)
Tel. 0543 739100 - Fax 0543 739123
e-mail: info@irst.emr.it PEC: direzione.generale@irst.legalmail.it

Capitale Sociale interamente versato Euro 20.000.000,00 - R.E.A. 288572 (FC)
Reg. Imprese FC / Cod. Fisc. / Partita IVA 03154520401
Codice di Interscambio: L0U7KO4

  Privacy policy e Cookies |   Login |   Portale IRST

Seguici su - Follow us on

bv logo

Questo sito fa uso di cookie tecnici

Questo sito fa uso di cookie tecnici, per permetterti la navigazione del sito, e per raccogliere statistiche anonime sull'utilizzo che ne fai. Scopri di più leggendo l'informativa.